CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Visualizações
• 07/14/23
0
0
Embutir
administrator
Assinantes
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários